



UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/662,457	09/11/2000	Henrik Sune Andersen	5956.200-US

Novo Nordisk of North America Inc  
Suite 6400  
405 Lexington Avenue  
New York, NY 10174-6401



FORMALITIES LETTER



\*OC000000005525943\*

Date Mailed: 11/02/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

*A copy of this notice **MUST** be returned with the reply.*

*M. Behane*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

02/09/2001 HAHMED1 00000041 141447 09662457

01 FC:105 130.00 CH



Attorney Docket No.: 5956.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Serial No.: 09/662,457

Group Art Unit: To be assigned

Filed: September 11, 2000

Examiner: To be assigned

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

**RESPONSE TO NOTICE TO FILE MISSING PARTS**

Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Notice to File Missing Parts dated November 2, 2000 (a copy thereof is attached hereto), Applicants submit the Combined Declaration and Power of Attorney (in 2 parts) signed and dated by Applicants for the above-captioned application.

~~Applicants also enclose certified copy of Danish application no. PA 1999~~  
01278, priority of which is claimed under 35 U.S.C. 119.

Please charge the required fee, estimated to be \$130.00, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 24, 2001

Steve T. Zelson, Reg. No. 30,335  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Attorney Docket No.: 5956.200-US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Serial No.: 09/662,457

Group Art Unit: To be assigned

Filed: September 11, 2000

Examiner: To be assigned

For: Modulators of Protein Tyrosine Phosphatases (PTPases)

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Petition and Fee For Extension of Time (in duplicate)
2. Response to Notice to File Missing Parts (in duplicate)
3. Copy of Notice to File Missing Parts
4. Executed Combined Declaration and Power of Attorney
5. Certified copy of Priority Application(s)
6. Power of Attorney

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on January 24, 2001.

Sylvia Gonzalez

(name of person mailing paper)

(signature of person mailing paper)